MLTX moonlaketx.com Earnings growth forecast for next year

Corporate emblem and logo of MoonLake (MLTX)

The outcomes of the final sonelokimab tests remain a critical factor for MoonLake Immunotherapeutics (MLTX). The estimated growth in net earnings per share for the coming year reflects market expectations, where the level of 0.50 is the current figure. The company's potential is based on patents for unique nanobodies designed to combat inflammation. Commercial success relies on the sales of innovative drugs to patients with autoimmune skin and joint pathologies.

MoonLake Pharma (MLTX): Expected net earnings per share growth next year from 04/28/2023 to 11/17/2026

MLTX (MoonLake Immunotherapeutics AG): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Initial company analysis:MLTX, moonlaketx.com
Finished products of MoonLake

To find a balance between asset value and business quality, it is essential to track the trajectory of analytical model revisions, which measures the risk of overvaluation through the dynamics of expected earnings. In the case of MoonLake Immunotherapeutics (MLTX), the shift in analyst estimates for EPS growth reflects market confidence in the commercial success of Sonelokimab and the efficacy of its unique nanobodies in clinical trials.

Analysis of competing companies

ASND (Ascendis) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Pharmaceuticals|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year RYTM (Rhythm Pharma)|Net earnings per share growth forecast for next year akerotx.com AKRO|Metsera Therapeutics (MTSR) - Expected net earnings per share growth next year|CRNX - Net earnings per share growth forecast for next year|NAMS: Net earnings per share growth forecast for next year|SLNO: Earnings growth forecast for next year|FOLD - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year 89bio Pharma|Agios Corp (AGIO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year structuretx.com (GPCR)|Expected earnings per share growth for next year mimedx.com MDXG|Net earnings per share growth forecast for next year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Net earnings per share growth forecast for next year|MBX: Expected earnings per share growth for next year|Altimmune Corp - Projected earnings per share increase next year|Aardvark Therapeutics Inc (AARD) - Net earnings per share growth forecast for next year|Net earnings per one share growth forecast for next year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth forecast for next year|Expected earnings per share growth for next year Biomea Fusion (BMEA)|Earnings growth forecast for next year QNCX|Projected earnings per share increase next year GUTS|Earnings growth forecast for next year VTVT (vTv Therapeutics Inc.)|Expected earnings per share trend next year ATPC|Pluristem Therapeutics - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year synlogictx.com SYBX|LPCN: Earnings growth forecast for next year|Matinas BioPharma Holdings, Inc. - Expected earnings per share trend next year|SPRB (Spruce Biosciences Inc.) - Earnings growth forecast for next year|galecto.com (GLTO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year organovo.com ONVO|Radius Health (RDUS) - Expected net earnings per share growth next year